Latest DHA-paclitaxel Stories
Study uncovers several compounds that inhibit cancer cell invasion, but also reveals that cancer drug paclitaxel does the oppositeâ€”it promotes cancer metastasis.
SEATTLE, Feb. 23, 2011 /PRNewswire/ -- Cell Therapeutics, Inc.
CALGARY, Jan. 18 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.
TUSTIN, Calif., Oct. 5 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today reported additional positive results in its Phase II trial evaluating bavituximab in combination with carboplatin and paclitaxel in patients with non-small cell lung cancer (NSCLC).
CALGARY, July 2 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that patient enrolment has been completed in the Phase II component of a Phase I/II U.K. trial of REOLYSIN combined with paclitaxel/carboplatin for patients with advanced cancers.
CALGARY, March 20 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced that interim clinical results from its Phase I/II U.K.
Peregrine Pharmaceuticals, a clinical stage biopharmaceutical company, has completed enrollment in the first stage of its Phase II trial evaluating a combination regimen of bavituximab with carboplatin and paclitaxel in patients with non-small cell lung cancer.
Pfizer has announced updated safety and efficacy results from a Phase II, randomized, non-comparative study surrounding its investigational compound, CP-751,871, in patients with non-small cell lung cancer.
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that two-year follow up survival data from its Phase 2b clinical trial in metastatic melanoma were presented at the 33rd Congress of the European Society for Medical Oncology (ESMO) in Stockholm.
- A trick or prank.